🔗 Visit the ClinicalTrials.gov page for NCT01393717
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. | Ther Adv Hematol | 2012 | 0.96 |
| 2 | Brentuximab vedotin. | MAbs | 2012 | 0.88 |
| 3 | Customized targeted therapy in Hodgkin lymphoma: hype or hope? | Hematol Oncol Clin North Am | 2014 | 0.82 |
| 4 | Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. | Pharmgenomics Pers Med | 2014 | 0.82 |
| 5 | Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. | Biol Blood Marrow Transplant | 2015 | 0.80 |
| 6 | Immunotherapy in pediatric malignancies: current status and future perspectives. | Future Oncol | 2014 | 0.78 |
| 7 | Advances in paediatric cancer treatment. | Transl Pediatr | 2014 | 0.76 |
| 8 | Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin. | BioDrugs | 2014 | 0.75 |